medigraphic.com
Colegio de Medicina Interna de México.

2014, Number 5

<< Back Next >>

Med Int Mex 2014; 30 (5)

Metformin and its current applications in the clinical setting

Castro-Martínez MG, Castillo-Anaya V, Ochoa-Aguilar A, Godínez-Gutiérrez SA

Language: Spanish
References: 72
Page: 562-574
PDF size: 526.32 Kb.


ABSTRACT

Metformin began to be used in the treatment of diabetes mellitus type 2 in Europe in 1957 and in the United States in 1995. Recently this drug has been the mostly prescribed oral anti-hyperglycaemic agent all over the word. In 1998 the United Kingdom Prospective Diabetes study demonstrated the anti-atherogenic effects of metformin and later it was discovered that the components of the syndrome of resistance to insulin (metabolic syndrome) were reduced with metformin. The Diabetic Prevention Program demonstrated the potential of metformin in the prevention of diabetes. Its efficiency, safety, multiple cardiovascular and metabolic benefits and its capacity to be combined with other antidiabetic drugs, which included insulin, have converted metformin the first option for the treatment of patients with diabetes mellitus type 2. In the last years it has been evident the role of metformin in patients with VIH and diabetes, fatty liver, as well as non diabetic patients mainly those with metabolic syndrome, with impaired glucose tolerance and women with desire to get pregnant, but suffer from polycystic ovarian syndrome. The role for prevention and treatment of cancer could be another development line of metformin in the future. The objective of this review is to update the new options for the use of this drug.


REFERENCES

  1. Inzucchi SE: Oral antihyperglycemic for type 2 diabetes. Scientific Review. JAMA 2002;287:360-372.

  2. Rosas J, Calles J, Friege F, Lara E, et al. Consenso de prediabetes. Documento de posición de la ALAD. Rev ALAD 2009;146-158.

  3. Diamanti-Kandarakis E, Christakou CHD, Kandaraki E, Economou N. Metformin: and old medication of new fashion: involving new molecular mechanism and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010;162:193-212.

  4. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989;12:553-564.

  5. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.

  6. Nattrass M, Alberti KGMM. Biguanides. Diabetologia 1978;14:71-74.

  7. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231-1245.

  8. Silvio E. Inzucchi. Oral antihyperglycemic for type 2 diabetes. Scientific Review JAMA 2002;287:360-372.

  9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 200;32:193-203.

  10. Inzucchi SE, Bergenstal RD, Buse GB, Diamant H, et al. Management of hyperglycemia in type 2 diabetes: A patient-Center Approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1-16.

  11. Adler AI, Shaw EJ, Stokes T, Ruiz F. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance 2009;338:1668.

  12. UK Prospective Diabetes Study (UKPDS). Group effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.

  13. Knowler W, Barrett-Connor E, Fowler S, Hammn R, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

  14. Graham GG, Punt J, Arora M, ODay R, et al. Clinical pharmacokynetics of metformin. Clin Pharmacokinet 2011;50:81-98.

  15. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-1431.

  16. Zhou G, Myers R, Li Y, Chen Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.

  17. Viollet B, Guigas B, Sanz Garcia N, Leclerc J. Cellular and molecular mechanisms of metformin: an overview. Clinical Science 2012;122:253-270.

  18. AACE comprehensive diabetes management algorithm 2013. Endocrine practice 2013;19:227-236.

  19. Bloomgarden Z. American College of Endocrinology prediabetes consensus conference: part 1;346:393-403.

  20. Fontbonne A, Charles M, Juhan-Vague I, Bard J, et al. The effect on metformin on the metabolic abnormalities associated with upper body fat distribution: BIGPRO Study Group. Diabetes Care 1996;19:920-926.

  21. Adreadis E, Katsanou D, Georgiopoulos G, Tsouros G, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects-the Carmos study. Exp Clin Endocrinol Diabetes 2009;117:175-180.

  22. Barrio R. Diabetes tipo 2 en la edad pediátrica. Pediatr Integral 2003;504-511.

  23. Giampatzis V, Tziomalos K. Management of type 2 diabetes mellitus in youth. World J Diabetes 2012;3:182-185.

  24. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 2000;23:381-389.

  25. Metzger BE, Lowe LP, Dyer AR, Trimble ER, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.

  26. Langer O. Management of gestational diabetes: Pharmacologic treatment options and glycemic control. Endocrinol Metab Clin N Am. 2006;35:53-78.

  27. Coetzee EJ, Jackson WP. The management of non-insulindependent diabetes during pregnancy. Diabetes Res Clin Pract 1985-1986;1:281-287.

  28. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-2015.

  29. Zanchia A, Lehmannb R, Philippe J. Antidiabetic drugs and kidney disease. Swiss Med Wkly 2012;142:13629.

  30. Piwkowska A, Rogacka D, Jankowski M, Dominiczak M, el al. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem. Biophys. Res Commun 2010;393:268-273.

  31. Takiyama Y, Harumi T, Watanabe J, Fujita Y, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes 2011;60:981-992.

  32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.

  33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared either conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837-853.

  34. Bailey CJ, Campbell IW, Chan JCN, Davidson JA, et al. Metformina y el peso corporal. En: Metformina, el tratamiento de referencia. Ed. Wiley, 2008;93-104.

  35. Kurukulasurlya R, Banerji MA, Chaiken R, Lebovitz H. Selective decrease in visceral fat is associated with weight loss during metformin treatment in Africa Americans with type 2 diabetes. Diabetes 1999;48:315.

  36. Yin M, van der Horst IC, van Melle JP, Qian C, et al. Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure. Am J Physiol. Heart Circ Physiol 2011;301:459-468.

  37. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574- 579.

  38. Chan JCN, Davidson JA. Mecanismos de protección vascular con metformina. En: Metformina, el tratamiento de referencia. Ed. Wiley, 2008;141-148.

  39. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. The emerging problem of nonalcoholic steatohepatitis (NASH). Rom J Gastroenterol 2005;14:43-51.

  40. Ekstedt M, Franzen LE, Mathiiesen UL, et al. Long-term follow up of patients with NAFDL and elevated liver enzymes. Hepatology 2006;44:865-873.

  41. Davidson JA, Chan JCN. Potencial de metformina en el tratamiento de los estados resistentes a la insulina. En: Metformina, el tratamiento de referencia. Ed Wiley 2008:141-158.

  42. Blaszyk H, Ferrentino N, Forsell S, et al. A pilot study of metformin as treatment for nonalcoholic steatohepatitis. Gastroenterology 2005;1288:769.

  43. Marchesini G, Brizi M, Blanchi G, Tomassetti S, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-894.

  44. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Fármacos que mejoran la resistencia insulínica para el hígado graso no alcohólico y la esteatohepatitis (Revisión Cochrane traducida). En: la Biblioteca Cochrane Plus 2008;4. Oxford: Update Software Ltd. Disponible en: http:// www.update-software.com.

  45. Uygun A, Kadayifci A, Isik At. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacol Ther 2004;19:537-544.

  46. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090.

  47. Braz Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. J Infect Dis 2010;14:256-263.

  48. Sweet DE. Metabolic complications of antiretroviral therapy. Topics in HIV Medicine 2005;13:70-74.

  49. Van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized atrial. Ann Intern Med 2005;143:337-346.

  50. Distrocoll SD, Meininger GE, Ljungquist K. Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2004;89:2171-2178.

  51. Discroll SD, Meininger GE, Laureau MT. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004;18:465-473.

  52. Handigan C, Corcoran C, Bazgoz N, Davis B, et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-477.

  53. Moghetti P. Insulin resistance: what is its role in the polycystic ovary syndrome? Curr Opin Endocrinol Diabetes 2002;9:444-450.

  54. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894-1901.

  55. Palomba S, Falbo A, Zullo F, Orio Jr F. Evidence-based and potential benefits of metformin in thepolycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50.

  56. Tosca L, Solnais P, Ferre P, Foufelle F, Dupont J. Metformininduced stimulation of adenosine 5-monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 2006;75:342-351.

  57. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, et al. Cellular and molecular mechanisms of metformin: an overview. Clinical Science 2012;122:253-270.

  58. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK the metabolic syndrome and cancer. Trends in Pharmacology Sciences 2005;26:69-76.

  59. Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol 2013;705:96-108.

  60. El-Mir MY, Nogueira V, Fontaine E, Averet N, et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-228.

  61. Pollak M. Insulin and insulin like growth factor signaling in neoplasia. Nat Rev Cancer 2008;915-928.

  62. Hawley SA, Davidson M, Woods A, Davies SP, et al. Characterization of the AMO-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMO-activated protein kinase. J Biol Chem 1996;271:27879-27887.

  63. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Soonenberg M. Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812.

  64. Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 2009;27:226.

  65. Ashinuma H, Takiguchi Y, Kitazono S, Kitazono-Saitoh M, et al. Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep 2012;28:8-14.

  66. Cantrell LA, Zhou C, Mendivil A, Malloy KM, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-98.

  67. Bhalla K, Hwang BJ, Dewi RE, Twaddell W, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012;5:544- 552.

  68. Kato K, Gong J, Iwama H, Kitanaka A, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012;11:549-560.

  69. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras- Ferraros C, et al. Metformin-induced preferential killing of breast cancer initiating CD44þCD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2þ human breast cancer xenografts. Oncotarget 2012;3:395-398.

  70. Dowling RJ, Goodwin J, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011;9:33.

  71. Asher G, Schibler U. Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab 2011;13;125-137.

  72. Um JH, Yang S, Yamazaki S, Kang H, et al. Activation of 5-AMP-activated kinase with diabetes drug metformin induces casein kinase Iε (CKIε)-dependent degradation of clock protein Per2. J Biol Chem 2007;282:20794-20798.




2020     |     www.medigraphic.com